Mon-Fri 9:00-18:00 CET+39 095 7211344info@vitasanlabs.com

Family · Pharmaceutical analytical standards

Baloxavir

An influenza antiviral discovered in Japan, where it was approved in February 2018, followed by the United States in October of the same year: it is a prodrug, baloxavir marboxil, taken as a single oral dose. This family brings together the active ingredient, labelled standards, nitrosamines and other impurities.

Did you know?It blocks 'cap snatching': the virus cuts the starting cap off the cell's messenger RNAs and uses it to launch its own. Baloxavir inhibits the enzyme that acts as the scissors.

BaloxavirGo to the active ingredient →
BaloxavirActive ingredientBaloxavirCat. No. P-B004-001CAS 1985605-59-1

Need a molecule you cannot find?

Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.